-

Flatiron Health Enters New Five-Year Research Collaboration with FDA on Real-World Data

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its renewed collaboration with the Oncology Center of Excellence (OCE) of the United States Food and Drug Administration (FDA) to jointly develop and implement specific research projects to advance the use of real-world data (RWD) and explore the potential strengths and limitations of using real-world evidence (RWE) for regulatory purposes. The partnership will specifically evaluate RWD study designs and analytic methods through the collaborative development of priority, clinically meaningful research questions regarding care, treatment, and outcomes of patients with cancer.

“Flatiron is honored to continue our collaboration with FDA,” said Javier Jimenez, Chief Medical Officer, Flatiron Health. “Together we will explore the potential strengths and limitations of using real-world evidence through investigations of a broad set of research questions regarding the care and clinical outcomes of patients diagnosed with solid tumors and hematological malignancies.”

Further, projects under this collaboration will explore approaches to define and assess fit-for-purpose relevant data on treatment exposure, patient outcomes, and covariates required to answer specific questions of interest. As part of the research process, Flatiron’s datasets will be analyzed to explore fit for purpose RWD, create real-world study protocols using best pharmacoepidemiology practices, and conduct observational studies. Additionally, the collaboration will enable Flatiron to provide FDA access to their datasets/platform, and highlight their suite of services, including cutting-edge analytics, scientific expertise, and strategic consulting.

About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth

Contacts

Media:
Flatiron Health
Nina Toor
communications@flatiron.com

Flatiron Health

Details
Headquarters: New York, NY
CEO: Nathan Hubbard
Employees: 2,500
Organization: PRI

Release Versions

Contacts

Media:
Flatiron Health
Nina Toor
communications@flatiron.com

More News From Flatiron Health

Flatiron Health's Breast Cancer Panoramic Dataset Surpasses One Million Patients, Enabling Real-World Research at Unprecedented Scale

NEW YORK--(BUSINESS WIRE)--Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced that its Breast Cancer Panoramic dataset has surpassed one million patients — the largest rigorously curated breast cancer real-world dataset of its kind. This milestone arrives during Breast Cancer Awareness Month, underscoring Flatiron's commitment to transforming patient experiences into evidence that advances care for peopl...

Flatiron Health Expands Global Panoramic Datasets With AI-Powered Breast Cancer and NSCLC Real-World Data for the UK, Germany, and Japan

NEW YORK--(BUSINESS WIRE)--Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced the launch of Breast Cancer and Non-Small Cell Lung Cancer (NSCLC) Panoramic datasets in the UK, Germany, and Japan. This marks the next phase of Flatiron's global evidence expansion, following the company's first multinational Panoramic data launch for prostate cancer in January 2026, to deliver longitudinal, AI-extracted real...

NCCN and Flatiron Health Announce Renewal of Collaboration to Advance Real-World Data Research Across Leading Cancer Centers

NEW YORK--(BUSINESS WIRE)--Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data (RWD), today announced the renewal of its collaboration with the National Comprehensive Cancer Network® (NCCN®), an alliance of leading cancer centers devoted to patient care, research, and education. The agreement, which dates back to 2014, extends through 2028 and reaffirms Flatiron's commitment to supporting real-world evidence (RWE) researc...
Back to Newsroom